
Strides Pharma Science Ltd is Rated Hold
2026-05-21 10:10:05Strides Pharma Science Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read MoreAre Strides Pharma Science Ltd latest results good or bad?
2026-05-19 19:19:02Strides Pharma Science Ltd's latest financial results for Q4 FY26 reflect a company navigating a complex operational landscape. The company achieved net sales of ₹1,323.47 crores, marking a year-on-year growth of 11.18% and indicating strong demand across its markets. This performance represents the highest quarterly revenue in the company's recent history, showcasing effective market penetration. However, the consolidated net profit for the quarter was ₹126.94 crores, which, while showing a year-on-year increase of 54.45%, also reflects a significant sequential decline of 37.19%. This volatility in earnings was primarily driven by a dramatic drop in other income, which fell from ₹106.86 crores in the previous quarter to just ₹8.13 crores, raising concerns about the sustainability of profit levels. Operating margins, excluding other income, compressed to 18.11% from 19.75% in the prior quarter, highlighti...
Read More
Strides Pharma Science Ltd Hits Intraday Low Amid Price Pressure on 19 May 2026
2026-05-19 09:31:20Strides Pharma Science Ltd experienced significant intraday weakness on 19 May 2026, with its stock price touching a low of Rs 1,045.8, marking a decline of 9.09% from the previous close. The stock underperformed its sector and broader market indices amid heightened volatility and persistent selling pressure.
Read More
Strides Pharma Science Ltd Reports Positive Quarterly Performance Amid Financial Trend Shift
2026-05-19 08:00:06Strides Pharma Science Ltd has demonstrated a commendable financial performance in the quarter ended March 2026, marking a positive shift in its financial trend. The company reported record-high net sales and operating profits, alongside a significant 27.1% growth in net profit after tax, signalling a strengthening position within the Pharmaceuticals & Biotechnology sector.
Read MoreWhen is the next results date for Strides Pharma Science Ltd?
2026-05-12 23:16:53The next results date for Strides Pharma Science Ltd is scheduled for 18 May 2026....
Read More
Broad-Based Technical Strength Lifts Strides Pharma Science Ltd to 52-Week High of Rs 1180.45
2026-05-12 10:35:16Surging past its previous peaks, Strides Pharma Science Ltd touched a new 52-week high of Rs 1180.45 on 12 May 2026, marking a remarkable 82.62% gain over the past year. This rally stands in stark contrast to the broader market’s subdued performance, with the Sensex down 8.71% over the same period.
Read More
Broad-Based Technical Strength Lifts Strides Pharma Science Ltd to 52-Week High of Rs 1174.7
2026-05-11 11:35:14Surging past Rs 1174.7 on 11 May 2026, Strides Pharma Science Ltd has marked a significant milestone by reaching a fresh 52-week high. This achievement caps an impressive rally of 82.66% over the past year, vastly outperforming the Sensex, which declined by 3.86% in the same period.
Read More
Strides Pharma Science Ltd is Rated Hold
2026-05-10 10:10:02Strides Pharma Science Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 06 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read More
Broad-Based Technical Strength Lifts Strides Pharma Science Ltd to 52-Week High of Rs 1174
2026-05-08 09:44:07Surging to a fresh 52-week high of Rs 1174 on 8 May 2026, Strides Pharma Science Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a subdued Sensex. The stock’s recent rally, marked by a four-day consecutive gain and an 11.9% return in that span, underscores a strong technical alignment that has propelled it well above key moving averages.
Read MoreAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
08-Jun-2026 | Source : BSEIntimation of Schedule of Analyst/ Institutional Investors Meet
Intimation Of Effective Date For The Scheme Of Demerger Involving Arco Lab Private Limited (Arco Lab) And Pivot Path Private Limited (Pivot Path)
01-Jun-2026 | Source : BSEIntimation of Effective Date for Scheme of Demerger involving Arco Lab Private Limited (Arco Lab) and (Pivot Path Private Limited).
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Reminder To Shareholders Regarding Unclaimed Dividends And Transfer To IEPF
01-Jun-2026 | Source : BSEReminder to Shareholders regarding Unclaimed Dividends and Transfer to IEPF
Corporate Actions
No Upcoming Board Meetings
Strides Pharma Science Ltd has declared 40% dividend, ex-date: 22 Jul 25
No Splits history available
No Bonus history available
No Rights history available